BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

744 related articles for article (PubMed ID: 17868725)

  • 1. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
    Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL
    J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
    Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
    J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes?
    Thong AE; Shikanov S; Katz MH; Gofrit ON; Eggener S; Zagaja GP; Shalhav AL; Zorn KC
    J Urol; 2008 Dec; 180(6):2436-40. PubMed ID: 18930486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate needle biopsies: multiple variables are predictive of final tumor volume in radical prostatectomy specimens.
    Poulos CK; Daggy JK; Cheng L
    Cancer; 2004 Aug; 101(3):527-32. PubMed ID: 15274065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2005 Mar; 12(3):270-4. PubMed ID: 15828954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and Gleason score to predict positive surgical margins.
    Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
    Urology; 2004 Sep; 64(3):516-21. PubMed ID: 15351582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
    Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
    Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
    Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
    J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population?
    Anast JW; Andriole GL; Bismar TA; Yan Y; Humphrey PA
    Urology; 2004 Sep; 64(3):544-50. PubMed ID: 15351590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should we replace the Gleason score with the amount of high-grade prostate cancer?
    Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
    Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
    Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
    J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Humphreys EB; Peck HJ; Trock BJ; Gonzalgo ML
    J Urol; 2007 Nov; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer volume at biopsy predicts clinically significant upgrading.
    Dong F; Jones JS; Stephenson AJ; Magi-Galluzzi C; Reuther AM; Klein EA
    J Urol; 2008 Mar; 179(3):896-900; discussion 900. PubMed ID: 18207180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Staging of prostate cancer: value of the combined information of endorectal MRI, biopsy Gleason score, and preoperative PSA level].
    Wetter A; Ajdukovic AN; Fliessbach K; Lehnert T; Engl T; Jacobi V; Vogl TJ
    Rofo; 2006 Apr; 178(4):385-90. PubMed ID: 16607587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database.
    Grossfeld GD; Chang JJ; Broering JM; Li YP; Lubeck DP; Flanders SC; Carroll PR
    J Urol; 2001 Mar; 165(3):851-6. PubMed ID: 11176485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The independent impact of extended pattern biopsy on prostate cancer stage migration.
    Master VA; Chi T; Simko JP; Weinberg V; Carroll PR
    J Urol; 2005 Nov; 174(5):1789-93; discussion 1793. PubMed ID: 16217288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors predicting prostatic biopsy Gleason sum under grading.
    Stackhouse DA; Sun L; Schroeck FR; Jayachandran J; Caire AA; Acholo CO; Robertson CN; Albala DM; Polascik TJ; Donatucci CF; Maloney KE; Moul JW
    J Urol; 2009 Jul; 182(1):118-22; discussion 123-4. PubMed ID: 19447436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
    Hattab EM; Koch MO; Eble JN; Lin H; Cheng L
    J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.